Federal investigators say that a Chinese drug manufacturer, previously on the Food and Drug Administration’s list of preapproved foreign companies allowed to import GLP-1 ingredients, was able to bring in batches of the weight loss drug from an unauthorized supplier and introduce the substance of unknown origin into the U.S. drug supply.In September 2025, now-ousted FDA Commissioner Marty Makary launched a so-called “green list” of overseas facilities permitted to ship active pharmaceutical ingredients for GLP-1 medication into the United States. The list is meant to prevent “potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from…